Physician

Pathology

Dr. Craig H. Mermel, MD

Craig Mermel works in the field of Pathology. Craig Mermel is also a published physician. He has 33 publication published. The most recent publication is: RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

Publications

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Age-related clonal hematopoiesis associated with adverse outcomes.
Computational pathology: an emerging definition.
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
Discovery and saturation analysis of cancer genes across 21 tumour types.
Pan-cancer patterns of somatic copy number alteration.
Mutational heterogeneity in cancer and the search for new cancer-associated genes.
Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma.
Recurrent hemizygous deletions in cancers may optimize proliferative potential.
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer.
How surgical residents use social media.
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers.
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset.
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.
The landscape of somatic copy-number alteration across human cancers.
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
Amplification of chromosomal segment 4q12 in non-small cell lung cancer.
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
Lin28 promotes transformation and is associated with advanced human malignancies.
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.
microRNA expression during trophectoderm specification.
Highly parallel identification of essential genes in cancer cells.
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity.
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis.
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
The 2013 symposium on pathology data integration and clinical decision support and the current state of field.

Schools

Harvard Medical School

Doctors Specialties

Pathology

Accepted Insurances

Education

Massachusetts General Hospital

Hospital

Massachusetts General Hospital

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Shahinaz A. Bedri, MD This Doctor is OpenDoctor Recommended.
	Dr. Ben Z. Pilch, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Matthew P. Frosch, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Jason F. Solus, MD This Doctor is OpenDoctor Recommended.
	Dr. Jacqueline M. William, MD This Doctor is OpenDoctor Recommended.
	Dr. Christopher J. Ianelli, MD This Doctor is OpenDoctor Recommended.
	Dr. Joseph M. Corson, MD This Doctor is OpenDoctor Recommended.
	Dr. Leonard D. Berman, MD This Doctor is OpenDoctor Recommended.